ClinicalTrials.gg

Program

MRNA-1083

A development code. Also written as “mRNA-1083”, “mRNA-1083.1” and “mRNA-1083.2”.

Its studies are mostly in Influenza, Human · COVID-19, led by Moderna.

Furthest: phase 3, since Oct 18, 20235 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Moderna50 open or runningphase 3since Oct 18, 2023Apr 24, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2023First study: phase 2 study in Influenza, HumanFirst studyNCT05827926 · 1,758 enrolled · United States
  2. Oct 18, 2023Phase 3 study in Influenza, HumanNCT06097273 · 8,061 enrolled · United States
  3. Jul 12, 2024Phase 2 study in Influenza, HumanNCT06508320 · 931 enrolled · United States, Canada
  4. Nov 15, 2024Phase 3 study in COVID-19NCT06694389 · 2,457 enrolled · Japan, South Korea, Taiwan
  5. Mar 5, 2025Phase 2 study in Influenza, HumanNCT06864143 · 1,320 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06864143Influenza, Human · United States2CompletedOct 13, 20251,320
NCT06694389COVID-19 · Japan, South Korea, Taiwan3CompletedNov 17, 20252,457
NCT06508320Influenza, Human · United States, Canada2CompletedSep 25, 2025931
NCT06097273Influenza, Human · United States3CompletedMay 28, 20248,061
NCT05827926Influenza, Human · United States2CompletedDec 3, 20241,758

How it is read

Names in the registry

  • “mRNA-1083”, 4 entries
  • “mRNA-1083.1”, 1 entry
  • “mRNA-1083.2”, 1 entry
  • “mRNA-1083.3”, 1 entry
  • “mRNA-1083 Composition 1 Dose A Lot A”, 1 entry

Codes read as this program: MRNA1083.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
MRNA-1083 (Moderna): development program | ClinicalTrials.gg